Radiation Treatment of the Prostate That is Specially Adjusted for Each Person
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A number of recent studies have successfully reduced the number of radiotherapy treatments used for prostate cancer from 39 daily treatments to as little as 5 treatments. This study is designed to determine how tumors inside the prostate respond during these 5 treatments on magnetic resonance imaging (MRI) and use that information to design 2 fraction radiotherapy treatments for prostate cancer. For these two fraction treatments, the first fraction of radiation will use extra radiation to any nodules in the prostate, and the second fraction of radiation will give extra radiation to the nodule(s) in the prostate based on how those nodules responded to the first fraction of radiation. This idea is a relatively old concept but has not been used in the treatment of cancer yet. This research includes a clinical trial that evaluates whether it is safe to design treatments like this.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem histologicznym rak gruczołu krokowego (adenocarcinoma)
- •Rak prostaty średniego lub wysokiego ryzyka
- •Wiek co najmniej 18 lat
- •Widoczny guz w prostatie na zdjęciu MRI
- •Brak wcześniejszej radioterapii miednicy
- •Spodziewana długość życia powyżej 10 lat
- •Kwalifikacja do specjalnej radioterapii prostaty (SBRT)
✗ Disqualifies
- •Brak widocznego guza w prostatie na zdjęciu MRI
- •Wcześniejsza operacja prostaty
- •Rak prostaty bardzo wysokiego ryzyka lub przerzuty do węzłów chłonnych
- •Aktywna choroba zapalna jelit
- •Przerzuty raka na inne części ciała
- •Choroby autoimmunologiczne takie jak toczeń rumień zakaźny
- •Niemożność uczestniczenia we wszystkich wizytach kontrolnych
- •Wcześniejsze leczenie hormonalne raka prostaty
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Jack Ady Cancer Centre
Lethbridge, Canada
Trial contact
Charlie Kirkby
Asongna Folefoc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.